Induction of hemoglobin F synthesis in patients with beta thalassemia.
5-Azacytidine transiently augments fetal hemoglobin production in patients with beta-thalassemia or sickle cell anemia. This change would probably be beneficial to such patients (e.g. a normal fetal gene product is substituted for a deficient or defective adult gene product) if HbF production could be sustained at high levels for prolonged periods. Even though the clinical use of 5-azacytidine is limited because of its presumed potential to cause cancer, studies with this drug have provided new insights into globin gene regulation and have stimulated the development of other strategies to increase HbF synthesis.
Ley
T J
TJ
Nienhuis
A W
AW
D000818:Animals; D001374:Azacitidine / Q000494:pharmacology / Q000627:therapeutic use*; D004247:DNA / Q000378:metabolism; D004900:Erythroblasts / Q000378:metabolism; D005260:Female; D005319:Fetal Hemoglobin / Q000096:biosynthesis* / Q000235:genetics; D005786:Gene Expression Regulation / Q000187:drug effects; D005914:Globins / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008745:Methylation; D010215:Papio; D013789:Thalassemia / Q000188:drug therapy* / Q000235:genetics
D005914:Globins; D004247:DNA; D005319:Fetal Hemoglobin; D001374:Azacitidine; D006918:Hydroxyurea